BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34784615)

  • 1. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
    Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
    Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
    Saccone G; Khalifeh A; Elimian A; Bahrami E; Chaman-Ara K; Bahrami MA; Berghella V
    Ultrasound Obstet Gynecol; 2017 Mar; 49(3):315-321. PubMed ID: 27546354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
    Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
    J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
    Megli C; Combs CA; Venkataramanan R; Lemon L; Caritis SN
    Am J Perinatol; 2022 Aug; 39(11):1183-1188. PubMed ID: 33321529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
    Hauspurg A; Lemon LS; Serra AE; Sharma S; Venkataramanan R; Caritis SN
    Am J Perinatol; 2018 Jul; 35(9):809-814. PubMed ID: 29294501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
    Manuck TA; Lai Y; Meis PJ; Dombrowski MP; Sibai B; Spong CY; Rouse DJ; Durnwald CP; Caritis SN; Wapner RJ; Mercer BM; Ramin SM
    Am J Obstet Gynecol; 2011 Aug; 205(2):135.e1-9. PubMed ID: 21600550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
    Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
    Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE; Sheffield J; Graham EM; Eke AC
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [No Abstract]   [Full Text] [Related]  

  • 17. Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.
    Sharma S; Caritis S; Hankins G; Miodovnik M; Hebert MF; Mattison D; Venkataramanan R
    Br J Clin Pharmacol; 2016 Oct; 82(4):1084-93. PubMed ID: 27133963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
    Zhang S; Rascati KL
    Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
    Caritis SN; Simhan HN; Zhao Y; Rouse DJ; Peaceman AM; Sciscione A; Spong CY; Varner MW; Malone FD; Iams JD; Mercer BM; Thorp JM; Sorokin Y; Carpenter M; Lo J; Ramin SM; Harper M;
    Am J Obstet Gynecol; 2012 Nov; 207(5):396.e1-8. PubMed ID: 22959763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.